HARBIN, China, Jan. 19 /PRNewswire-Asia/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company developing and producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that it has been featured by 'Science and Technology Daily,' an authoritative and influential publication in China covering science, technology, and innovation.
The 8,000-word long article in 'Science and Technology Daily' chronicles China Sky One Medical's 15-year history as it went from being a small distributor of medicines in China to a leading developer and producer of high quality pharmaceuticals listed on the NASDAQ Global Select Market. From the author's perspective, the Company's strong research and development capabilities have given it an edge over thousands of medicine manufacturers in China. From the very beginning, China Sky One Medical made a decision to invest significantly in research and development, which has turned out to be a core competency for the Company.
The article reported that China Sky One Medical's bio-engineering medical laboratory and Traditional Chinese Medicine (TCM) laboratory are both considered key provincial laboratories. China Sky One Medical is now developing several cancer diagnostic kits through its Heilongjiang Research Center for Bio-engineering Diagnostic Products. In addition, the Company has built long-term cooperative relationships with Harbin Medical University and many other research institutions.
"We are delighted that 'Science and Technology Daily' decided to profile China Sky One in this way so that our innovative approach and portfolio of pharmaceutical products can benefit more and more people," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "Going forward, we will continue to focus our efforts in developing more new proprietary medical products to create value for both customers and shareholders."
To view the full article in Chinese, please click on: http://www.stdaily.com/kjrb/content/2009-12/15/content_135509.htm .
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include expectations of future growth or information regarding the move to new headquarters. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
For more information, please contact:
Company Contact:
China Sky One Medical, Inc.
Mr. Stanley Hao, CFO
Tel: +86-0451-8703-2617
Email: stanleyhao@cski.com.cn
Investor Relations Contact:
CCG Investor Relations
Mr. Crocker Coulson, President
Tel: +1-646-213-1915
Email: crocker.coulson@ccgir.com
Web: http://www.ccgirasia.com
Mr. R. Micchelli, Sr. Financial Writer
Tel: +1-646-454-4516
Email: richard.micchelli@ccgir.com
